Latest Period
Q2 2026
Security Snapshot
Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE) Institutional Ownership
CUSIP: 00773J202
13F Institutional Holders and Ownership History from Q3 2023 to Q2 2026
Institutions Reporting
261
Shares (Excl. Options)
95,741,305
Price
$88.78
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value
- Symbol
- SYRE on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 95,741,305
- Total 13F value
- $8,510,174,258
- Portfolio coverage rank
- 0.01%
- Share change
- +12,361,844
- Value change
- +$1,397,131,473
- Number of holders
- 261
- Shares outstanding
- 88,583,250
- SEC-reported price per share
- $102.70
- Insider filing price
- $102.70
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- SYRE - Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value is tracked under CUSIP 00773J202.
- 261 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 196 to 261 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $4,162,740,265 to $8,510,174,258.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 261 institutions filings for Q2 2026.
Security key
00773J202
Latest holder period
Q2 2026
13F holders
261
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
SYRE full holder history
Spyre Therapeutics, Inc. SEC filings
Spyre Therapeutics, Inc. company facts
Spyre Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00773J202:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
SYRE
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 10% | 0% | $697,101,864 | +$46,907,483 | 9,667,201 | +7.2% | Peter Evan Harwin | 23 Jun 2026 |
| PERCEPTIVE ADVISORS LLC | 4.9% | -2% | $383,312,075 | 4,319,496 | 0% | Perceptive Advisors LLC | 30 Jun 2026 | |
| RTW INVESTMENTS, LP | 4.8% | -23% | $377,322,125 | +$55,906,200 | 4,251,996 | +17% | RTW Investments, LP | 30 Jun 2026 |
| BlackRock, Inc. | 6.6% | $59,323,024 | 3,962,635 | BlackRock, Inc. | 30 Jun 2025 | |||
| Venrock Healthcare Capital Partners III, L.P. | 4.6% | $40,335,429 | 2,685,448 | Venrock Healthcare Capital Partners III, L.P. | 31 Dec 2024 | |||
| TANG CAPITAL MANAGEMENT LLC | 2.4% | -58% | $62,064,160 | -$42,895,840 | 1,892,200 | -41% | TANG CAPITAL MANAGEMENT, LLC | 31 Dec 2025 |
As of 30 Jun 2026, 261 institutional investors reported holding 95,741,305 shares of Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE). This represents 108% of the company’s total 88,583,250 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
83%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 13,026,187 | +11% | 0.05% | $1,156,464,882 |
| BlackRock, Inc. | 7.3% | 6,506,605 | +18% | 0.01% | $577,656,391 |
| PERCEPTIVE ADVISORS LLC | 4.9% | 4,319,496 | +14% | 6% | $383,484,855 |
| RTW INVESTMENTS, LP | 4.8% | 4,251,996 | +1.9% | 3.2% | $377,492,205 |
| Paradigm Biocapital Advisors LP | 4.3% | 3,840,778 | +96% | 6.4% | $340,984,271 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 3,448,681 | +13% | 0.01% | $306,173,899 |
| STATE STREET CORP | 3.5% | 3,057,416 | +17% | 0.01% | $271,437,392 |
| Venrock Adviser, LLC | 3.4% | 2,985,448 | -19% | 8% | $265,048,073 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.3% | 2,960,855 | +85% | 0.03% | $262,866,000 |
| Driehaus Capital Management LLC | 3.2% | 2,799,166 | +0.3% | 1.4% | $248,509,957 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.9% | 2,562,265 | +49% | 0.01% | $239,258,122 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.6% | 2,330,098 | +298% | 0.01% | $206,866,100 |
| Capital World Investors | 2.6% | 2,315,553 | +247% | 0.02% | $205,574,795 |
| Jupiter Topco LLC | 2.5% | 2,206,936 | 0% | 0.08% | $195,881,358 |
| TCG Crossover Management, LLC | 2.1% | 1,900,582 | 0% | 4.1% | $168,733,670 |
| TANG CAPITAL MANAGEMENT LLC | 2.1% | 1,892,200 | 0% | 7.6% | $167,989,516 |
| BANK OF AMERICA CORP /DE/ | 2% | 1,777,854 | +45% | 0.01% | $157,837,878 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.9% | 1,722,300 | 0.21% | $152,905,794 | |
| WELLINGTON MANAGEMENT GROUP LLP | 1.8% | 1,581,505 | -13% | 0.02% | $140,406,014 |
| GOLDMAN SACHS GROUP INC | 1.7% | 1,478,059 | +448% | 0.01% | $131,222,079 |
| FRANKLIN RESOURCES INC | 1.7% | 1,472,943 | +67% | 0.03% | $130,767,861 |
| Remedium Capital Partners, LLC | 1.7% | 1,464,169 | +0.55% | 29% | $129,988,924 |
| Affinity Asset Advisors, LLC | 1.4% | 1,279,134 | 0% | 5.6% | $113,561,517 |
| JPMORGAN CHASE & CO | 1.2% | 1,093,026 | +12% | 0.01% | $98,870,628 |
| Holocene Advisors, LP | 1.1% | 1,015,170 | 0.21% | $90,126,793 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
12
Latest
Q2 2026
Rows shown
1-12 of 12
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 95,741,305 | $8,510,174,258 | +$1,397,131,473 | $88.78 | 261 |
| 2026 Q1 | 82,649,625 | $4,162,740,265 | +$97,012,962 | $50.44 | 196 |
| 2025 Q4 | 80,976,878 | $2,652,563,796 | +$541,005,178 | $32.76 | 152 |
| 2025 Q3 | 64,298,657 | $1,077,601,900 | +$12,200,602 | $16.76 | 136 |
| 2025 Q2 | 63,624,754 | $952,552,077 | +$19,485,332 | $14.97 | 128 |
| 2025 Q1 | 62,108,053 | $1,004,204,799 | +$22,237,875 | $16.14 | 128 |
| 2024 Q4 | 59,883,954 | $1,394,038,124 | +$171,655,898 | $23.28 | 129 |
| 2024 Q3 | 51,375,323 | $1,511,815,633 | +$36,820,905 | $29.41 | 118 |
| 2024 Q2 | 50,382,939 | $1,184,222,119 | +$421,575,660 | $23.51 | 106 |
| 2024 Q1 | 31,640,426 | $1,196,964,043 | +$172,560,163 | $37.93 | 101 |
| 2023 Q4 | 28,010,905 | $600,997,673 | +$524,495,293 | $21.52 | 54 |
| 2023 Q3 | 3,257,983 | $39,909,852 | +$39,909,852 | $12.25 | 27 |